Ambu Valuation

Is AMBU B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AMBU B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow

Simply Wall St

DKK 140.01

Fair Value

4.6% undervalued

Number of Analysts

Below Fair Value: AMBU B (DKK133.6) is trading below our estimate of fair value (DKK140.01)

Significantly Below Fair Value: AMBU B is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AMBU B?

Key metric: As AMBU B is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for AMBU B. This is calculated by dividing AMBU B's market cap by their current earnings.
What is AMBU B's PE Ratio?
PE Ratio	109.2x
Earnings	DKK 326.00m
Market Cap	DKK 35.59b

AMBU B key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6.3x
Enterprise Value/EBITDA	38.6x
PEG Ratio	4.2x

Price to Earnings Ratio vs Peers

How does AMBU B's PE Ratio compare to its peers?

The above table shows the PE ratio for AMBU B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	31.2x
DEMANT Demant	19.4x	9.2%	DKK 56.1b
EMBLA Embla Medical hf	28.7x	14.0%	DKK 14.1b
COLO B Coloplast	36.1x	14.4%	DKK 176.5b
ITGR Integer Holdings	40.6x	21.5%	US$4.8b
AMBU B Ambu	109.2x	25.9%	DKK 35.6b

Price-To-Earnings vs Peers: AMBU B is expensive based on its Price-To-Earnings Ratio (109.2x) compared to the peer average (31.3x).

Price to Earnings Ratio vs Industry

How does AMBU B's PE Ratio compare vs other companies in the European Medical Equipment Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: AMBU B is expensive based on its Price-To-Earnings Ratio (109.2x) compared to the European Medical Equipment industry average (32.7x).

Price to Earnings Ratio vs Fair Ratio

What is AMBU B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AMBU B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	109.2x
Fair PE Ratio	38.7x

Price-To-Earnings vs Fair Ratio: AMBU B is expensive based on its Price-To-Earnings Ratio (109.2x) compared to the estimated Fair Price-To-Earnings Ratio (38.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AMBU B forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	DKK 133.60	DKK 141.03 +5.6%	16.6%	DKK 165.00	DKK 90.00	n/a	8
Jan ’26	DKK 104.00	DKK 127.70 +22.8%	18.5%	DKK 160.00	DKK 76.00	n/a	7
Dec ’25	DKK 111.00	DKK 127.63 +15.0%	18.5%	DKK 160.00	DKK 76.00	n/a	7
Nov ’25	DKK 129.70	DKK 128.67 -0.8%	18.5%	DKK 145.00	DKK 76.00	n/a	6
Oct ’25	DKK 130.00	DKK 125.50 -3.5%	19.1%	DKK 145.00	DKK 76.00	n/a	6
Sep ’25	DKK 127.95	DKK 126.40 -1.2%	21.9%	DKK 160.00	DKK 76.00	n/a	5
Aug ’25	DKK 140.60	DKK 117.00 -16.8%	25.0%	DKK 138.00	DKK 59.00	n/a	5
Jul ’25	DKK 136.55	DKK 117.00 -14.3%	25.0%	DKK 138.00	DKK 59.00	n/a	5
Jun ’25	DKK 131.40	DKK 111.20 -15.4%	24.9%	DKK 138.00	DKK 59.00	n/a	5
May ’25	DKK 111.95	DKK 107.20 -4.2%	26.4%	DKK 130.00	DKK 52.00	n/a	5
Apr ’25	DKK 113.55	DKK 107.20 -5.6%	26.4%	DKK 130.00	DKK 52.00	n/a	5
Mar ’25	DKK 121.45	DKK 107.20 -11.7%	26.4%	DKK 130.00	DKK 52.00	n/a	5
Feb ’25	DKK 111.60	DKK 105.00 -5.9%	26.7%	DKK 130.00	DKK 52.00	DKK 134.75	5
Jan ’25	DKK 105.20	DKK 85.67 -18.6%	26.2%	DKK 115.00	DKK 47.00	DKK 104.00	6
Dec ’24	DKK 91.94	DKK 85.67 -6.8%	26.2%	DKK 115.00	DKK 47.00	DKK 111.00	6
Nov ’24	DKK 69.86	DKK 89.40 +28.0%	28.2%	DKK 120.00	DKK 53.00	DKK 129.70	5
Oct ’24	DKK 73.86	DKK 95.60 +29.4%	25.6%	DKK 120.00	DKK 53.00	DKK 130.00	5
Sep ’24	DKK 83.56	DKK 96.00 +14.9%	25.3%	DKK 120.00	DKK 53.00	DKK 127.95	5
Aug ’24	DKK 99.16	DKK 101.80 +2.7%	27.0%	DKK 135.00	DKK 59.00	DKK 140.60	5
Jul ’24	DKK 111.65	DKK 102.60 -8.1%	26.9%	DKK 135.00	DKK 59.00	DKK 136.55	5
Jun ’24	DKK 107.50	DKK 102.60 -4.6%	26.9%	DKK 135.00	DKK 59.00	DKK 131.40	5
May ’24	DKK 105.50	DKK 101.60 -3.7%	28.4%	DKK 135.00	DKK 55.00	DKK 111.95	5
Apr ’24	DKK 102.75	DKK 96.25 -6.3%	30.8%	DKK 135.00	DKK 55.00	DKK 113.55	4
Mar ’24	DKK 101.35	DKK 104.60 +3.2%	30.2%	DKK 140.00	DKK 55.00	DKK 121.45	5
Feb ’24	DKK 99.14	DKK 87.80 -11.4%	20.6%	DKK 110.00	DKK 65.00	DKK 111.60	5

Analyst Price Target

Consensus Narrative from 8 Analysts

DKK 141.03

Fair Value

5.3% undervalued

Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/06 05:09
End of Day Share Price	2025/02/06 00:00
Earnings	2024/12/31
Annual Earnings	2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ambu A/S is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	ABG Sundal Collier
Michael Healy	Berenberg
Alexander Berglund	BofA Global Research